Nanoarchitectonics: Complexes and conjugates of platinum drugs with silicon containing nanocarriers. an overview

13Citations
Citations of this article
12Readers
Mendeley users who have this article in their library.

Abstract

The development in the area of novel anticancer prodrugs (conjugates and complexes) has attracted growing attention from many research groups. The dangerous side effects of currently used anticancer drugs, including cisplatin and other platinum based drugs, as well their systemic toxicity is a driving force for intensive search and presents a safer way in delivery platform of active molecules. Silicon based nanocarriers play an important role in achieving the goal of synthesis of the more effective prodrugs. It is worth to underline that silicon based platform including silica and silsesquioxane nanocarriers offers higher stability, biocompatibility of such the materials and pro-longed release of active platinum drugs. Silicon nanomaterials themselves are well‐known for improving drug delivery, being themselves non‐toxic, and versatile, and tailored surface chemistry. This review summarizes the current state‐of‐the‐art within constructs of silicon‐containing nanocarriers conjugated and complexed with platinum based drugs. Contrary to a number of other re-views, it stresses the role of nanochemistry as a primary tool in the development of novel prodrugs.

Cite

CITATION STYLE

APA

Piorecka, K., Kurjata, J., & Stanczyk, W. A. (2021, September 1). Nanoarchitectonics: Complexes and conjugates of platinum drugs with silicon containing nanocarriers. an overview. International Journal of Molecular Sciences. MDPI. https://doi.org/10.3390/ijms22179264

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free